Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Christina Loefgren"'
Autor:
Frida Schain, Yuliya Leontyeva, Robert Szulkin, Christina Loefgren, Jianming He, Magnus Björkholm
Publikováno v:
HemaSphere, Vol 7, p e6046738 (2023)
Externí odkaz:
https://doaj.org/article/9c93ce6b6103423ba8df62c477146832
Autor:
Christina Loefgren, Catherine Thieblemont, Peter O'Donovan, Christoph Tapprich, Jamie Garside, JM Quigley, Neerav Monga, Binu Gurung, Loretta J. Nastoupil
Publikováno v:
PharmacoEconomics Open
Background Follicular lymphoma (FL) and marginal zone lymphoma (MZL) are types of indolent non-Hodgkin lymphoma (NHL) that develop in the B lymphocytes (also known as B cells). Objective The aim of this study was to conduct a comprehensive review of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac93de1232245a9380229aaa324e60de
https://doi.org/10.1007/s41669-020-00204-z
https://doi.org/10.1007/s41669-020-00204-z
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S135
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6fabb9a1c164899d4335b71bd11a9d19
https://doi.org/10.1016/s2152-2650(22)00814-x
https://doi.org/10.1016/s2152-2650(22)00814-x
Publikováno v:
Journal of geriatric oncology. 13(7)
Introduction Patient-reported outcomes (PROs) predict overall survival (OS) in many cancer types, but there is little evidence of their prognostic value in older patients with acute myeloid leukemia (AML). We examined whether the Functional Assessmen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84b80c464e519bba5a5cb086160577ff
https://pubmed.ncbi.nlm.nih.gov/35778351
https://pubmed.ncbi.nlm.nih.gov/35778351
Background: This retrospective analysis evaluates morbidities, outcomes and associated risk factors in patients with myelofibrosis (MF) after ruxolitinib discontinuation, using Truven Health Analytics MarketScan (TR), Optum integrated virtual electro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eaa3bdd37bffcdd73282dc20844ed5f3
Autor:
Frida Schain, Maren Gaudig, Kristina Sandström, Annica Dominicus, Christina Victoria Jones, Magnus Björkholm, Christina Loefgren
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S212
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::483316dfaa93a59bf0c96fb00067bebc
https://doi.org/10.1016/s2152-2650(21)01332-x
https://doi.org/10.1016/s2152-2650(21)01332-x
Autor:
Maren Gaudig, Kristina Sandstrom, Christina Loefgren, Magnus Björkholm, Annica Dominicus, Frida Schain, Christina Victoria Jones
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S287
Context: There is limited recent population-based data on outcomes for novel agents and different treatment combinations in acute myeloid leukemia (AML) patients judged ineligible for intensive chemotherapy. Objective: To characterize patients, treat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::60a9a98e11e10216bbd85b9f63a479d4
https://doi.org/10.1016/s2152-2650(21)01688-8
https://doi.org/10.1016/s2152-2650(21)01688-8
Autor:
Susan Yount, Christina Loefgren, Jianming He, Renee Pierson, F. Efficace, David Cella, John Devin Peipert
Publikováno v:
CancerReferences. 126(15)
BACKGROUND The objective of this study was to validate the Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu) in patients with acute myeloid leukemia (AML) who are not candidates for intensive therapy. METHODS A sample of 317 patients with A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e45f7b079c5dc58c50420a688afb928
https://pubmed.ncbi.nlm.nih.gov/32463931
https://pubmed.ncbi.nlm.nih.gov/32463931
Autor:
Jianming He, Susan Yount, Fabio Efficace, John Devin Peipert, David Cella, Renee Pierson, Christina Loefgren
Publikováno v:
Journal of Clinical Oncology. 38:7532-7532
7532 Background: Patient-reported outcomes (PROs) predict overall survival (OS) in solid cancer populations, but little evidence exists around the prognostic value of PROs in patients with hematologic malignancies. We investigated whether scales from
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2db067427534a48cacccd407d5ecb210
https://doi.org/10.1200/jco.2020.38.15_suppl.7532
https://doi.org/10.1200/jco.2020.38.15_suppl.7532
Publikováno v:
Blood. 132:3590-3590
Introduction: Acute Myeloid Leukemia (AML) is an aggressive disease associated with poor health related quality of life (HRQoL) and short overall survival (OS), particularly for patients' ineligible for intensive chemotherapy. The HRQoL was evaluated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::89ea0b213ba1de12f5bcb1243c8cb751
https://doi.org/10.1182/blood-2018-99-114635
https://doi.org/10.1182/blood-2018-99-114635